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MicroRNA regulation of endothelial TREX1
reprograms the tumour microenvironment
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Rather than targeting tumour cells directly, elements of the tumour microenvironment can be
modulated to sensitize tumours to the effects of therapy. Here we report a unique mechanism
by which ectopic microRNA-103 can manipulate tumour-associated endothelial cells to
enhance tumour cell death. Using gain-and-loss of function approaches, we show that
miR-103 exacerbates DNA damage and inhibits angiogenesis in vitro and in vivo. Local,
systemic or vascular-targeted delivery of miR-103 in tumour-bearing mice decreased
angiogenesis and tumour growth. Mechanistically, miR-103 regulation of its target gene TREX1
in endothelial cells governs the secretion of pro-inﬂammatory cytokines into the tumour
microenvironment. Our data suggest that this inﬂammatory milieu may potentiate tumour
cell death by supporting immune activation and inducing tumour expression of Fas and TRAIL
receptors. Our ﬁndings reveal miR-mediated crosstalk between vasculature and tumour cells
that can be exploited to improve the efﬁcacy of chemotherapy and radiation.
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V
ascular endothelium is a highly complex, dynamic organ
with a growing list of sophisticated functions. As such, the
endothelial cells (ECs) encounter a variety of insults and
injuries during pathogenesis and have developed intricate stress
response pathways that enable cell survival decisions. Intrigu-
ingly, emerging studies suggest that DNA damage response
pathways (DDR) in ECs play a pro-angiogenic role1,2.
The histone H2AX and an efﬁcient DDR were shown to
be important for EC proliferation under hypoxia and hypoxia-
related angiogenesis1. Similarly, the ataxia telangiectasia-mutated
kinase, a master regulator of the DDR drives pathological
angiogenesis2. Given the critical role of hypoxia, oxidative stress
and DNA damage in the tumour microenvironment, under-
standing the molecular basis of how ECs deal with these stressors
will enable the development of a new class of DDR-targeted
therapies for regulation of angiogenesis. Indeed, it has been
proposed that EC death is one of the critical determinants of
radiation damage3,4, a key therapeutic modality in cancer
treatment. Since miRs inﬂuence several aspects of endothelial
function5, we hypothesized that miRs regulate endothelial
apoptosis in response to radiation damage. We have identiﬁed
a microRNA (miR) signature in ECs induced in common by
genotoxic stress, oxidative stress and DNA damage. We demon-
strate that the most upregulated miR in this signature, miR-103, is
a negative regulator of EC DNA repair, cell survival and sprouting
angiogenesis in vitro. Importantly, we observe that exogenous
miR-103 expression inhibits both developmental and pathological
angiogenesis in vivo. We show that miR-103 targets non-
canonical DNA repair enzymes, three prime exonucleases
(TREX) 1 and 2 in ECs. MiR-103 regulation of TREX1 induces
several pro-inﬂammatory cytokines and a type I interferon
response in vitro. Indeed, vascular-targeted delivery of miR-103
induces proinﬂammatory cytokines, costimulatory molecules and
decreases PD-L1þ macrophages and neutrophils in the tumour
microenvironment. Taken together, our data identiﬁes miR-103
regulation of TREX1 as a potent modulator of the tumour
microenvironment.
Results
DDR induces miR-103 and miR-103 exacerbates DNA damage.
We observed that silencing of the microRNA processing enzyme
Dicer in human umbilical vein ECs signiﬁcantly increased DNA
damage in these cells as measured by a Comet assay
(Supplementary Fig. 1). We reasoned that individual miRs cap-
able of inducing a DDR in vascular cells may represent a powerful
therapeutic strategy to sensitize tumours to the effects of therapy.
To identify speciﬁc miR(s) involved in this function, we screened
for miRs that were differentially expressed in ECs 6 h after irra-
diation or treatment with cisplatin or hydrogen peroxide
(Supplementary Fig. 2) and found miR-103 as the top candidate
among a set of seven miRs upregulated in response to all three
inducers of intrinsic apoptosis (Fig. 1a,b). We ﬁrst asked if miR-
103 upregulation was a typical response to cell stress across a
panel of cell types. Surprisingly, we found that miR-103 was
preferentially upregulated in primary vascular cells including ECs
and vascular smooth muscle cells but not in a range of other cells
such as pancreatic and brain tumour cells (Fig. 1c). Indeed,
irradiation of an orthotopic 4T1 mammary carcinoma resulted in
rapid upregulation of miR-103 in the tumour ECs but not in the
non-EC fraction (Fig. 1d). Moreover, we found that primary miR-
103 was transcribed as early as 30min after radiation (Fig. 1e) and
in response to a range of doses from 2 to 20Gy (Fig. 1f
and Supplementary Fig. 3). We then asked whether miR-103 had
a functional role in response to DNA damage induced by
radiation. Indeed ectopic expression of miR-103 mimic
exacerbated DNA double strand (ds) breaks induced by radiation
as measured by phosphorylation of histone H2AX, while inhibi-
tion of miR-103 decreased the ds breaks induced by radiation
(Fig. 1g,h and Supplementary Fig. 4a). Consistently, miR-103
induced exacerbation of DNA damage in the presence of radia-
tion was also apparent in a neutral comet assay (Supplementary
Fig. 4b).
miR-103 induces EC death and inhibits sprouting angiogenesis.
We then asked if there were functional consequences due to
miR-103-mediated DNA damage in ECs. Surprisingly, transfec-
tion of miR-103 in ECs signiﬁcantly increased markers of
apoptosis, cleaved caspase-3 and poly (ADP-ribose) polymerase
(PARP) even in the absence of radiation and in combination with
a single dose of radiation (Fig. 2a and Supplementary Fig. 5)
suggesting that miR-103 functions as a pro-apoptotic miR
(apoptomiR) in ECs. Interestingly, the apoptotic effects of miR-
103 were lost upon EC culture in minimal growth conditions in
basal medium (Supplementary Fig. 6) suggesting that this miR
may be apoptotic only to proliferating ECs. Conversely, inhibition
of miR-103 decreased the activation of caspases 3 and 7 induced
by radiation (Fig. 2b). To further dissect the physiological con-
sequences of miR-103, we examined its activity in a three-
dimensional sprouting angiogenesis assay6. Consistent with its
pro-apoptotic function, miR-103 expression resulted in a 50%
decrease in endothelial sprouting (Fig. 2c). Inhibition of
endogenous miR-103 induced by radiation rescued sprouting
angiogenesis in vitro (Fig. 2d) and in an FGF Matrigel plug
angiogenesis model in vivo (Fig. 2e and Supplementary Fig. 7).
Having established the anti-angiogenic role of miR-103 in vitro,
we asked if it had an effect in vivo using a developmental
angiogenesis model in neonatal mouse retinas7. Intraocular
injection of miR-103 into postnatal day 5 pups decreased
retinal neovascularization in the deep plexus by 50% over a
control miR (Fig. 2f). These observations led us to conﬁrm that
miR-103 is not only expressed in response to genotoxic stress but
also functions as an apoptomiR that can suppress angio-
genesis in vitro and in vivo.
miR-103 diminishes angiogenesis and tumour burden.
We sought to address if miR-103 is sufﬁcient to decrease
pathological angiogenesis and tumour burden in vivo. Since
anti-angiogenic agents have been successful in the treatment of
glioblastomas and colorectal carcinomas8–10, we chose to investi-
gate the effects of miR-103 in mouse xenograft models of these
two tumour types. Strikingly, local delivery of miR-103 a week
after tumour implantation increased survival in an aggressive
orthotopic glioblastoma model (Fig. 3a). Moreover, treatment
of subcutaneous HCT-116 colon carcinoma xenografts with three
doses of a miR-103 mimic and a single dose of radiation
signiﬁcantly decreased tumour burden (Fig. 3b) when compared
with mice that received a control mimic. Consistent with our
in vitro observations on angiogenic sprouting, there was a 60%
decrease in vascular area (CD31 staining) in mice that received
both miR-103 and radiation (Fig. 3c) a week after the last
miR-103 injection. To address whether this effect was speciﬁcally
due to the action of miR-103 on the tumour endothelium, we
utilized a recently characterized11,12 EC targeted nanoparticle
7C1 to deliver miR-103. We observed that intravenous injection
of 7C1-miR-103 resulted in an approximately threefold enrich-
ment of miR-103 in tumour ECs but not in the non-EC fraction
(Supplementary Fig. 8). Delivery of a 10-fold lower dose of
miR-103 mimic (0.7mg kg 1) alternating with a 2Gy dose
fraction of radiation was sufﬁcient to decrease tumour burden
(Fig. 3d) concomitant with a signiﬁcant decrease in CD31 area
(Fig. 3e). It has been observed that anti-angiogenic agents can
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potentially cause an increase in metastasis in breast cancer13,14.
Therefore, we asked if our miR-103 treatment could impact
growth and/or metastasis of a highly aggressive triple negative
mammary carcinoma 4T1 in syngeneic Balb/C mice. We found
that while miR-103 had a modest but measurable effect on
tumour burden (Fig. 3f), there was a signiﬁcant decrease in the
number of lung metastases (Fig. 3g). Indeed, consistent with our
other tumour models, we also observed a decrease in CD31 area
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Figure 1 | miR-103 is upregulated during DNA damage and exacerbates DNA ds breaks. (a) Venn diagrams showing miR proﬁling results from HUVECs
treated with the indicated genotoxic agents and (b) expression levels of the top seven upregulated miRs (at least 1.5-fold cutoff). The numbers indicate fold
change over control treated HUVECs normalized to a housekeeping small RNA at 6 h post treatment. (c) Heatmap depicting expression of miR-103 in
different vascular cell types 6 h after radiation. Numbers depict mean fold increases over mock-treated cells. (d) qRT-PCR showing the expression of
miR-103 in ECs 3 h post radiation in a 4T1 mammary carcinoma model. N¼ 3 mice per group and two tumours per mouse. Bars show meanþ s.e.m.
* indicates Po0.05 by two-tailed Student’s t-test. (e) qRT-PCR assay showing induction of miR-103 transcript (pri-miR) in HUVECs over time after a single
20Gy dose of radiation. Meanþ s.e.m. of two biological replicates is shown (f) qRT-PCR of pri-miR-103 in HUVECs 1 h after indicated doses of radiation.
One of two representative experiments (g,h) Phosphorylation of histone H2AX in HUVECs measured by immunoﬂuorescence staining 24 h after ectopic
expression of miR-103 (g) and inhibition of miR-103 (h) 3 h after exposure to the indicated doses of radiation. Bars show meanþ s.e.m. of pixel area
normalized to the number of nuclei for 25–50 nuclei per group. * indicates Po0.05 by two-tailed Student’s t-test. qRT-PCR; quantitative real-time PCR.
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(Fig. 3h) indicating the impact of the miR treatment on
angiogenesis. Our observations with both gain-and-loss of
function of miR-103 in vitro and in developmental and
pathological angiogenesis models in vivo argue that miR-103
decreases angiogenesis.
miR-103 targets DNA repair pathway enzymes. miRs are
thought to exert signiﬁcant effects on gene expression programs
by binding to mRNAs, generally at their 30-untranslated region
(30-UTR) and recruiting them to an RNA-induced silencing
complex (RISC) for degradation15. To investigate the target(s) of
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Figure 2 | miR-103 induces EC death and decreases sprouting angiogenesis in vitro and in vivo. (a,b) Apoptosis, as measured by cleaved PARP and
caspase-3, 48 h after ectopic expression of miR-103 (a) or (b) a caspase Glo- luminescence assay for active caspases 3 and 7 after ectopic expression of
miR-103 in HUVECs 48 h after exposure to the indicated doses of radiation. One out of three independent experiments. Bars show meanþ s.e.m.
** indicates Po0.01 by two-tailed Student’s t-test. (c) 3D angiogenic sprouting assay with expression of miR-103. Right panel bars show meanþ s.e.m. of
lectin stained sprout areas from at least 10 beads per group. *Po0.05 by two-tailed Student’s t-test. Scale bar, 100mm. One of four independent
experiments. (d) 3D angiogenic sprouting assay with expression of Anti-miR-103. Right panel bars show meanþ s.e.m. of lectin stained sprout areas from
at least 10 beads per group. *Po0.05 by two-tailed Student’s t-test. Scale bar, 100 mm. One of three independent experiments. (e) Quantiﬁcation of
angiogenesis in mouse Matrigel plugs after i.v injection of control or miR-103 inhibitor followed by 10Gy local radiation (N¼4–6 plugs per group, one out
of the three independent experiments). Bars show meanþ s.e.m. * indicates Po0.05 by two-tailed Student’s t-test. (f) Whole mount images of mouse
neonatal P12 retina stained with anti-CD31 5d post intraocular injection with miR-103. Right panel bars show meanþ s.e.m. of CD31 area from n¼ 5 retinas.
*Po0.05 by two-tailed Student’s t-test. Scale bar, 200 mm.
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miR-103 relevant to its role as an apoptomiR in ECs, we
compared mRNA expression levels for 92 genes using a Taqman
DNA damage-related gene signature panel for ECs that were
treated with radiation alone or transfected with miR-103 mimic
(Supplementary Fig. 9). Surprisingly, only three mRNAs were
downregulated in both groups—the 30-exonucleases TREX1 and
TREX2 and the fanconi anaemia complementation group F gene,
FANCF. Mutations in TREX1 have been associated with several
human diseases including systemic lupus erythematosus and
retinal vasculopathy with cerebral leukodystrophy (RVCL)16–18.
Coincidentally, RVCL has been described as a disease with loss of
capillaries in the retina and the brain pathology has been noted to
be similar to radiation damage19. We utilized a RISC-Trap
assay20 and observed that miR-103 transfection resulted in robust
enrichment of TREX1 and a modest level of FANCF transcripts
associated with the RISC (Fig. 4a). Human TREX1 mRNA has a
short 30-UTR that does not contain any putative miR-103-
binding sites. RNA hybrid modelling identiﬁed two high-afﬁnity
binding sites A and B in the coding region of TREX1
(Supplementary Fig. 10). FANCF on the other hand has one
miR-103 binding site in the 30UTR (Supplementary Fig. 10).
Consistent with the enrichment in the RISC-Trap assay, ectopic
expression of miR-103 decreased both mRNA and protein levels
of TREX1, TREX2 and FANCF (Fig. 4b,c and Supplementary
Fig. 11). Moreover, one of the TREX1 sites, site A and the FANCF
site decreased the expression of an upstream luciferase by more
than 60% (Fig. 4d). Mutations that disrupted miR-103 binding on
TREX1 site A restored the luciferase levels (Supplementary
Fig. 12) indicating that miR-103 directly binds to TREX1 in this
region. Indeed, knockdown of TREX1 recapitulated the miR-103-
induced apoptosis (Fig. 4e) and sprouting angiogenesis (Fig. 4f),
whereas the silencing of FANCF had more modest effects.
Importantly, expression of a target protector, an oligonucleotide
sequence that is complementary to the TREX1 miR-103 binding
site but speciﬁc to TREX1 was able to rescue miR-103 mediated
decrease in sprouting angiogenesis (Fig. 4g) indicating the
decrease of TREX1 is the major mechanism by which miR-103
mediates EC death and suppresses angiogenesis. Finally, we
examined TREX1 and FANCF levels in the tumour ECs from a
xenograft GBM model and found signiﬁcant downregulation of
both at the RNA level (Supplementary Fig. 13). Similarly 4T1
tumours treated with our EC targeted miR-103 had signiﬁcant
downregulation of TREX1 staining in the tumour endothelium
(Supplementary Fig. 13).
miR-103 inhibition of TREX1 induces interferons. Since loss of
TREX1 has been linked to accumulation of ssDNA, defective
DNA repair and elaboration of cytokines21,22, we asked if
miR-103 regulated the expression of cytokines using a multi-
plex chemokine/cytokine assay. Indeed, miR-103 expression
signiﬁcantly upregulated proinﬂammatory chemokines IP-10,
RANTES, MIG and cytokines IL-15, IL-12 and IFN-g (Fig. 5a).
Importantly, the miR-103 mediated induction of these factors was
diminished in the presence of a TREX1 target protector (Fig. 5a
and Supplementary Fig. 14) indicating that these chemokines and
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Figure 3 | miR-103 decreases angiogenesis and tumour burden.
(a) GBM-NS-001 cells (2 104) were orthotopically implanted into brains
of nude mice. miRs were injected locally 7 days post tumour implantation
(N¼ 14 mice per group). P value from a log-rank (Mantel–Cox) test.
(b) HCT116 colon carcinoma cells were implanted subcutaneously in nude
mice. Mice were treated with 50mg of either control miR or miR-103 mimic
on days 6, 8 and 10 (black arrows). Mice received a single dose of 2Gy
radiation on day 8 (red arrows). Mean tumour volume measurements of
N¼8 mice per group are shown. Error bars represent s.e.m. *Po0.05 by
Mann–Whitney U-test. (c) Angiogenesis was measured by staining tumour
sections with anti-CD31. Quantiﬁcation of CD31 area from at least three
mice per group are shown. Bars show meanþ s.e.m. *Po0.05, **Po0.01.
(d) HCT cells were implanted as in b. (N¼8 mice per group) Mice were
treated with either a control mimic or mir-103 mimic in 7C1 nanoparticles
(0.7mg kg 1 of miR, i.v.) on days 9,12 and 15 (black arrows) and were
irradiated locally on days 10,12 and 16 (red arrows). Mean tumour volume
measurements of N¼8 mice per group are shown. Error bars represent
s.e.m. *Po0.05 by Mann–Whitney U-test. (e) Angiogenesis was measured
as in c. Bars show meanþ s.e.m. *Po0.05 by two-tailed Student’s t-test.
(f,g) 4T1 mouse mammary carcinoma cells (1 104) were implanted in the
mammary fat pads of 6–8 week old female Balb/C mice (N¼6 controls,
7 treated). Mice were randomized to receive either Control miR or miR-103
mimic formulated as miR-7C1 nanoparticles (0.7mg kg 1, i.v.) on days 12,
14, 16. Primary tumour volume measurements and gross metastatic foci per
lung on day 20 are shown. Error bars depict s.e.m. *Po0.05 and **Po0.01
by Mann–Whitney U-test. (h) Angiogenesis was measured by staining the
4T1 tumour sections with anti-CD31. Bars show CD31 area normalized the
tumour area as meanþ s.e.m. from n¼4 tumours per group. *Po0.05 by
two-tailed Student’s t-test.
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cytokines are speciﬁcally regulated by miR-103 mediated decrease
in TREX1. The most upregulated chemokine in our miR-103
supernatants, IP-10 has recently been shown to be induced in
lymphoblasts from patients with RVCL and in TREX1 V235fs
mutation knock-in mice23. Consistent with our in vitro data,
we observed a signiﬁcant increase in IP-10 mRNA levels in
tumour ECs from our 7C1-miR-103 treated mice (Supplementary
Fig. 15a). IP-10 is a well-known negative regulator of angiogenesis
in vitro and in vivo24–26. Our cytokine proﬁle also indicates
coordinated regulation of related cytokines. For example, IL-12 is
known to elevate the production of IFN-g which, in turn, induces
the production of IP-10 and MIG27. Some of these cytokines, that
is, IL-12 and IFNs are also regulators of cell death pathways.
Indeed, we found that miR-103 induced both IP-10 and IFNa2
(Fig. 5b). In fact, we found there was a robust upregulation of
canonical interferon stimulated genes MX1 and OAS1 (Fig. 5c).
We found that these increases were dependent on TREX1 and not
FANCF (Fig. 5c). Therefore, we hypothesized that the cytokine
milieu from the ECs expressing miR-103 may also promote
tumour cell death in a paracrine fashion. To test this hypothesis,
we used an apoptosis protein array and found that miR-103
treatment in mice led to a signiﬁcant upregulation of several
pro-apoptotic pathways in the HCT-116 tumours, particularly a
B30-fold increase in the levels of Fas and TRAIL-Rs (Supple-
mentary Fig. 15b). Indeed, conditioned media from miR-103
transfected ECs upregulated HCT-116 expression of Fas and
TRAIL receptors in a TREX1-dependent manner (Supple-
mentary Fig. 15c). Similarly, conditioned media from either
miR-103 transfected ECs or TREX1-silenced ECs upregulated Fas
transcription in MDA-MB-231 breast cancer cells (Fig. 5d).
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from two independent experiments. *Po0.05 by two-tailed Student’s t-test. (d) Luminescence from 30-UTR-luciferase constructs with indicated miR-103
binding regions 24 h after transfection with miR-103. *Po0.05 by two-tailed Student’s t-test. One out of two independent experiments. (e) Apoptosis as
measured by cleaved PARP and caspase-3 48 h after knockdown of FANCF, TREX1. One of four independent experiments. (f) 3D angiogenic sprouting
assay after knockdown of FANCF, TREX1. *Po0.05 by two-tailed Student’s t-test. One out of three independent experiments. *Po0.05 by two-tailed
Student’s t-test. (g) 3D sprouting assay using HUVECs transfected with indicated oligos. All bars show meanþ s.e.m. *Po0.05, **Po0.01 by ANOVA.
3D, three-dimensional; ANOVA, analysis of variance; qRT-PCR, quantitative real-time PCR.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13597
6 NATURE COMMUNICATIONS | 7:13597 | DOI: 10.1038/ncomms13597 | www.nature.com/naturecommunications
Finally, inhibition of Fas with an antagonistic antibody decreased
the miR-103-mediated activation of Caspase-8 (Supplementary
Fig. 15d). Our data suggests that radiation induced miR-103
downregulates TREX1 in ECs, decreases angiogenesis and leads to
the secretion of proinﬂammatory mediators that may upregulate
Fas and TRAIL pathways in tumour cells. We tested this
hypothesis by interrogating the 4T1 tumour lysates from mice
treated with control miR or miR-103 (described in Fig. 3f,g) using
a proteome proﬁler western blot membrane array. In addition to
key chemokines, we also saw a signiﬁcant increase in
costimulatory receptors CD40, CD160, adhesion molecules and
receptors for advanced glycation end products (Fig. 5e).
Interestingly, we also saw a decrease of the immune checkpoint
ligand PD-L1 expression on macrophages and neutrophils in the
tumours (Supplementary Fig. 16) as well as a decrease in the
numbers of these immunosuppressive cells in the tumours28
suggesting that miR-103 treatment may modulate the immune
microenvironment.
Discussion
Our ﬁndings demonstrate that miR-103 is a potent apoptomiR
that can decrease angiogenesis via regulation of TREX1/FANCF.
Previous studies have shown that miR-103 has been shown to be
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Figure 5 | miR-103 treatment induces an inﬂammatory secretome in vitro and in vivo. (a) Cytokines upregulated at least twofold in HUVECs transfected
with miR-103 or miR-103 in the presence of a TREX1 target protector. Mean fold change of two independent biological replicates vs control miR in a
multiplex cytokine assay are depicted. (b) qRT-PCR of IP-10 (CXCL10) and IFNa1 and IFNa2 from HUVECs transfected with a control mimic or miR-103
mimic. Fold change at 24 h post transfection compared with control mimic is depicted. Bars show meanþ s.e.m. One out of three independent experiments.
(c) mRNA levels of canonical interferon-stimulated genes MX1, OAS1 and EIF2AK2 from HUVECs transfected with the indicated micro-RNAs and target
protector oligos. Bars show meanþ s.e.m. *Po0.05 by two-tailed student’s t-test compared with control miR. (d) Fas expression on MDA-MB-231 human
breast cancer cells 24 h after exposure to conditioned media from HUVECs transfected with the indicated RNAs. Bars show mean fold changeþ s.e.m.
*Po0.05, **Po0.01 by ANOVA. One of three independent experiments. (e) Quantitation of protein expression from 4T1 tumour lysates from either
control treated mice or miR-103 treated mice (experiment in Fig. 3f) using a western blot membrane array. Mean spot density of two independent tumours
is shown. Signiﬁcantly different proteins (*Po0.01 by two-tailed Student’s t-test) are depicted. Bars show meanþ s.e.m. (f) Schematic representation
depicting putative mechanism of action of miR-103. ANOVA, analysis of variance; qRT-PCR, quantitative real-time PCR.
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involved in diverse physiological processes including metastasis
control29, insulin sensitivity30 and resistance to EGFR inhibition
in lung cancer31. Interestingly, Taniguchi and colleagues identi-
ﬁed miR-103 as one of the top miRs in a functional screen for
DNA damage disrupting agents that affect chemotherapy
sensitivity32. They identiﬁed Rad51 and Rad51D as key targets
of miR-103/miR-107 that enabled the effects of the miRs in
enhancing chemosensitivity of tumour cells. Chen et al.33 have
shown miR-103/107 are late response genes in hypoxia and
function together with Let-7a/7e to regulate AGO1 and VEGF
pathways that leads to an increase in angiogenesis. However,
since their treatment approaches used a combination of three
miR inhibitors (Anti-let7a, let7e and miR-103), the speciﬁc role of
miR-103 in ECs remains unclear. Consistent with our miR-103
ﬁndings, miR-107 which shares the same seed sequence as miR-
103, has been reported to decrease tumour angiogenesis34. Our
gain and loss of function experiments in vitro and in vivo argue
that miR-103 is a negative regulator of angiogenesis.
We have identiﬁed a TREX1 as a novel target for miR-103 in
endothelial DDRs. While TREX1 has not been considered a
canonical DNA repair enzyme, recent studies highlight a broader
role for this exonuclease. For example, TREX1 has been shown to
interact with PARP and facilitates its nuclear localization and
activity35. In addition to ssDNA, TREX1 has now been implicated
in the degradation of dsDNA and ssRNA36,37. In fact, TREX1 has
even been shown to have nuclease independent activities in the
regulation of oligosaccharyltransferase that contributes to its role
in immune regulation23. Moreover, studies have shown that
deregulation of TREX1 can mediate inﬂammation38,39. Our
observations demonstrate another unique but critical role for
TREX1 downstream of miR-103 in promoting EC death and
dysfunction in response to radiation. The elaboration of
proinﬂammatory mediators by miR-103 is also dependent on
TREX1 and suggests that both cell intrinsic and extrinsic
mechanisms play a role in miR-103 function.
It is increasingly clear that the tumour microenvironment,
particularly the vasculature plays a critical role in tumour
progression and responses to therapeutics40,41. Our data
highlights a novel molecular mechanism that not only regulates
EC death in DDRs but also provokes an inﬂammatory milieu that
could both diminish pro tumorigenic cells such as PD-L1þ
macrophages and sensitize the surrounding tumour cells to death
receptor pathways. We believe these results elucidate a complex
crosstalk between endothelial DNA damage and the tumour
microenvironment that can be exploited to augment treatment
regimens in cancer.
Methods
Cell culture and reagents. HUVECs (Lonza) were cultured in EBM-2 media
(Lonza) supplemented with bullet kit and 10% fetal calf serum (Hyclone).
HCT-116 cells (ATCC), 4T1 cells (ATCC) were culture in McCoy’s media, DMEM
or RPMI-1640 supplemented with 10% fetal calf serum and antibiotics. Cells were
tested and found negative for mycoplasma contamination before use in the assays
described.
Western blotting. Cell and tissue lysates were prepared in RIPA buffer (Pierce
89900) and quantiﬁed using a BCA assay (Pierce, #23227) kit. Equivalent amounts
of protein were loaded on a 4–12% gradient SDS-polyacrylamide gel (NuPAGE,
Life-Technologies) or a 8% SDS–polyacrylamide gel and transferred overnight onto
polyvinylidene diﬂuoride (PVDF) membranes. Membranes were blocked in 5%
milk or 3% BSA and incubated with antibodies as indicated- Trex1 (Cell Signaling
12215 s 1:1,000 o/n), Fancf (Abnova, h00002188-bo1p 1:1,000 o/n), anti-b-actin
antibody (Sigma, A5316, 1:10,000 1 h RT). Membranes were washed in TBST and
incubated with secondary antibodies from Licor Biosciences were used goat anti
mouse 925-68020 (1:15,000) and goat anti rabbit 925-32211 (1:15,000). Blots were
scanned on the Licor Odyssey scanner according to manufacturer’s instructions.
For speciﬁc protein array experiments with membrane arrays -mouse XL cytokine
Array (R&D Biosystems-ARY028) and human apoptosis array (R&D Biosystems
ARY009), protocols were according to manufacturer’s instructions.
Vectors/plasmids. FANCF Luciferase-30-UTR plasmid was purchased from
SwitchGear Genomics. TREX1 luciferase constructs were cloned by inserting a
B70 bp fragment of the miR-103-binding region into a pmiR-REPORT vector
(Ambion). Luciferase assay reagents were purchased from Switch Gear Genomics.
miRs/anti-miRs/siRNAs. miR-103 mimics, inhibitors and respective controls
were purchased from Life Technologies and Exiqon. For in vivo studies,
high-performance liquid chromatography-puriﬁed miRs were purchased from
Life Technologies in bulk quantities. SiRNAs against TREX1 and FANCF were
purchased from Life Technologies.
Gapmer TREX1 and TREX1, FANCF target protectors were purchased from
Exiqon.
Transfections. Cells were transfected at 50–60% conﬂuence using standard for-
ward transfection protocols using RNAimax reagent (Life Technologies) for miRs/
siRNAs and Lipofectamine 2000 for plasmid or plasmid RNA dual transfections.
Typically 50 nM RNA and 1–2 mg plasmid DNA were used for transfections. Target
protectors were transfected at a concentration of 50 nM or equivalent to the miR
amounts.
Radiation of cells/mice. Cells or mice were irradiated on a Shepherd 137cesium
irradiator at a rate ofB166 cGymin 1. In tumour-targeted radiation experiments,
mice were restrained in a lead shield (Brain Tree Scientiﬁc) to minimize exposure
to the non-tumour areas.
RNA extraction and real time PCR assays. RNA was extracted using miRVana
microRNA isolation kit (Ambion) and PCR with reverse transcription (RT–PCR)
was performed using multiplexed TaqMan primers (Applied Biosystems). The miR
proﬁles were generated with a 384-well microﬂuidic card based TaqMan human
microRNA panel (Applied Biosystems) ampliﬁed on a 7900 HT Fast Real Time
PCR system (Applied Biosystems). HUVECs were treated with either a 20Gy dose
of radiation or 10mM cisplatin or 200 mM hydrogen peroxide or 10ngml 1 of
TNF-a for 6 h. At the end of the treatment, RNA was extracted using miRvana
microRNA isolation kit (Ambion). 1,000 ng of RNA was reverse transcribed
without pre-ampliﬁcation using the Taqman Megaplex primer pools A and B and
real-time PCR was performed on the microﬂuidic cards for the human microRNA
panels A & B per manufacturer’s recommendation (Applied Biosystems). Data was
normalized to internal control small RNA RNU48 or U6 small RNAs. mRNAs
were normalized to either b-actin or GAPDH. Individual RT–PCRs were per-
formed using predesigned TaqMan Assays for mature miRs, primary miRs or
mRNAs (Applied Biosystems) on a SmartCycler (Cepheid) or Vii-7 real-time PCR
platform (Applied Biosystems) according to manufacturer’s instructions.
Apoptosis assays. HUVECs were transfected with miRs/Anti-miRs using
Lipofectamine RNAi Max reagent (Life Technologies). Apoptosis was measured
by either a caspase 3/7-luciferase assay kit (Promega) or ﬂow cytometry with
anti-cleaved caspase-3 (Cell Signaling Technologies 9579S: 1:200) and anti-cleaved
PARP antibodies (Cell Signaling Technologies 5625: 1:200) or western blot for
cleaved caspase-3 (Abcam Ab136812 1:300) according to manufacturer’s
instructions.
3D angiogenic sprouting assay. Early passage HUVECs were coated on cytodex-
3 (GE Healthcare) beads at a density of 10 million cells per 40 ml beads and
incubated in suspension for 3–4 h with gentle mixing every hour. They were plated
on TC treated 6 well dishes overnight and resuspended in a 2mgml 1 ﬁbrin gel
with 200,000 human smooth muscle cells. The gel was allowed to polymerize
and complete EGM-2 media was added. Sprouts were visualized from days 3 to
4 via confocal imaging after overnight incubation with 1:200 ﬂuorescein iso-
thiocyanate (FITC)-labelled Ulex europaeus lectin (Vector labs).
Comet assay. Ionizing radiation induced DNA double strand breaks were
measured using neutral comet tail assay. Cells were irradiated, harvested, and
then assayed using the Trevigen CometAssay kit. Comet tail length in pixels was
measured using CometScore freeware (TriTek Corp). A total of 50–100 cells were
analysed in each sample group.
cH2AX staining. A total of 100,000 HUVECs were cultured on glass coverslips in
24-well plates and transfected with miRs/siRNAs using RNAimax (Life Technol-
ogies). Plates were irradiated 24 h post transfection and cells were ﬁxed at different
time points with 4% paraformaldehyde for 10min at room temperature, permea-
bilized with 90% methanol for 10min at 4 C. Coverslips were blocked with 1.5%
normal goat serum and incubated with primary antibody (H2AX Abcam 11174 1:
1,000) in normal goat serum for 1 h, washed and then incubated with secondary
antibody for 30min, washed and then mounted on glass slides for confocal
imaging.
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miR in situ hybridization. In situ hybridization was performed on frozen tumour
sections as described by Pena et al.42 using a DIG labelled miR-103 Locked Nucleic
Acid (LNA) probe (Exiqon). DIG was detected by an anti-DIG HRP antibody
(Roche) and ampliﬁed using a TSA-Plus Cy3 system (Perkin Elmer).
miR-TRAP/RISC TRAP assay. HUVECs or 293 T cells were co-transfected with a
plasmid coding for a ﬂag-tagged dominant negative GW418 mutant (Clontech
kit #632016) along with a control mimic or miR-103 mimic according to kit
instructions. Twenty-four hours later the RNA protein complexes were crosslinked
and the RISC complex was immunoprecipitated using an anti-FLAG antibody and
RNA was isolated for quantitative real-time PCR of target genes. The fold
enrichment was calculated using pre and post IP controls as well as normalization
to the control mimic pull-downs.
In vivo assays. All animal work was approved by the UCSD Institutional Animal
Use and Care Committee or OHSU Institutional Animal Use and Care Committee.
Immune-compromized 8–10-week-old female nu/nu mice purchased from the
UCSD Animal Care Program breeding colony or Jackson Labs were injected
subcutaneously with 2 million mycoplasma-negative HCT116 tumour cells in
Matrigel (BD). Tumour growth was measured with calipers, with volume
computed as ½  LengthWidth2. Mice were randomized into groups once the
average tumour volume reached 80–150mm3, approximately 6 days after injection.
For some experiments, mice were treated with 7C1-nanoparticles containing
miR-103 or control miR (0.7mg kg 1, i.v.). GBM-NS-001 cells (2 104 cells in 4 ul
HBSS) were stereotactically injected into the brains of 5–6-weeks-old nude mice.
The coordinates were: 1.8mm to the right of bregma and 3mm deep from
the dura. miRNA was delivered 7 days post injection. 4T1 cells (1 104) were
implanted into the mammary fat pad #4 of 6–8 week old female Balb/C mice in
100ml Matrigel. Mice were randomized into groups once the average tumour
volume reached 150mm3, B10 days after implantation. Mice were treated with
7C1-nanoparticles containing miR-103 or control miR (0.7mg kg 1, i.v.). Mice
were killed Bday 18–20 for analysis of metastatic burden in lungs. For analysis
of immune cells from the tumour microenvironment, mice were perfused with
10–15ml PBS/heparin before harvest of tumours. Mice with a 420% decrease in
body weight were killed and tumours conﬁrmed by histology. For miR measure-
ment studies (Fig. 1d), 4T1 tumours were implanted in the mammary fat pad of
Balb/C mice and allowed to grow to a size of B300mm3. Tumour-bearing mice
were irradiated with the indicated doses (0, 2 or 20Gy). Mice were killed 3 h post
radiation, tumours were harvested for EC isolation followed by quantitative
real-time PCR.
Matrigel plug angiogenesis assay. Growth factor reduced Matrigel (BD) with
400 ngml 1 recombinant human bFGF (Millipore) was injected subcutaneously in
Balb/C mice. Mice were injected i.v with 10 mg control or anti-miRs 3 days after
plugs were implanted. Four days later mice were irradiated with the indicated doses
on a Shepherd 137cesium irradiator at a rate of B166 cGymin 1. 3 days after
irradiation mice were injected with 10 mg FITC-conjugated Griffonia simpliﬁcola
lectin, the plugs were harvested, lysed in RIPA-buffer and the FITC content was
measured on a spectrophotometer (Glomax, Promega) with a standard FITC ﬁlter
set.
Retinal angiogenesis assay. Retinal neovascularization studies were performed as
described elsewhere43. Brieﬂy, 5 mg of either control mimic or miR-103 mimic was
injected into the vitreous cavity of 6-day-old neonatal Balb/C mice under topical
analgesia. 6 days later mice were killed, the retinas were dissected, ﬁxed and stained
with anti-CD31 antibodies (BD Pharmingen 553372, 1:500 overnight at 4 C).
Endothelial cell sorting and RT–PCR. Five to six-week-old Nu/Nu mice were
injected with GBM-NS-001 cells (2 106) subcutaneously. 20 days post injection,
mice were randomized to two groups—control miRNA (n¼ 5) or miR103 (n¼ 5).
15 nmoles of miR was delivered by tail vein injection. 48 h later, tumours were
harvested followed by enzymatic digestion and ECs were isolated as CD45-
CD31þCD34þ cells by ﬂow cytometry cell sorting. RNA was isolated from the
ECs and RT–PCR was performed to determine the gene expression. Primers are
listed as below
FANCF forward 50-CGCTGGCTTCTCGAAAGTC-30 reverse 50-CCAGGCAC
CCTTTTGCAGAT-30
TREX1 forward 50-CGTCAACGCTTCGATGACAAC-30 reverse 50- CTCA
GCCTAGCAAGCTCTGT-30
GAPDH forward 50-ATCATCCCTGCCTCTACTGG-30 reverse50-GTCAGG
TCCACCACTGACAC-30
Endothelial cell isolation. Tumours were harvested from mice and mechanically
digested using razor blade. Tissue was incubated in collagenase type I (1mgml 1)
(Worthington, #ls004214) for 1 h at 37 C. The reaction was stopped with EGM2
media 10% fetal bovine serum (FBS) and the solution was ﬁltered with a 70-mm cell
strainer. Cells were resuspended in 1ml of cold media and incubated at 4 C for
20min. After that time cells were incubated with CD31 antibody (Genetex
Gtx54379 1:400 in PBS) during 30min at 4 C with shaking. Cells were incubated
with anti-Rat-IgG magnetic beads (1:50 in EGM2) for 30min. CD31-positive cells
were selected with a magnetic rack and kept in RNA later until isolation.
Single cell isolation. Mice were perfused with a 15ml solution of PBS/Heparin.
Tumour were harvested and and mechanically digested. Tissue was incubated in
collagenase type II (2mgml 1) during 1 h at 37 C. The reaction was stopped with
DMEM 10% FBS and the solution was ﬁltered with a 70 mm cell strainer. Cells were
frozen in DMEM 10% DMSO and 1mgml 1 BSA until the staining for FACS
analysis.
Single cell staining. Cells were plated on a 96-well plate (2 106 cells per well),
blocked with Fc-Block (BD Bioscience, cat # 553142) 1:200 and Live/ Death Aqua
reagent solution 1:500 for 25min on ice. Subsequently cells were stained with an
antibody cocktail mix containing the following antibodies with the indicated
ﬂuorophores—CD11C (563057, BD Biosciences, BV605 1:200), CD11B (563401,
BD Biosciences, BV771 1:400), PDL1 (12-5982, eBioscience, PE 1:200), CD45
(25-0451, eBioscience, PE-Cy7 1:500), F4/80 (17-4801-80, eBioscience, APC 1:300)
and Ly6G (127623, Biolegend APC-Cy7 1:200) in FACS buffer (PBS 2% FBS and
1mM EDTA) for another 25min. After external staining cells were ﬁxed with
Cytoﬁx Buffer (BD Bioscience, cat # 554655). After the staining cells, were washed
and resuspended in 200 ul of FACS buffer and stored at 4 C protected from light
until analysis in a BD-LSR-Fortessa cell analyser. Data was analysed with FACS-
DIVA software.
Immunoﬂuorescence and microscopy. In some experiments, TREX1 was
visualized using immunoﬂuorescence staining from OCT sections of tumour tissue.
Slides were ﬁxed with 4% PFA and stained overnight for Trex1 (BD bioscience
611986 1:200 o/n). Imaging was performed on a Nikon Spectral C1 confocal
microscope (Nikon C1si with EZC1 acquisition software, Nikon Instruments) with
Plan Apo 10X/0.45 air, Plan Apo 20X/0.75 air, and Plan Apo 60X/1.40 oil objective
lenses (Nikon). Some immunoﬂuorescence imaging was performed on a Yokogawa
CSU-W1 spinning disk confocal microscope with  20 0.45 Plan Fluor objective
(Nikon). All images were taken with a channel series. Images were analysed with
Image J software for determination of CD31 or lectin area.
Luminex cytokine panels. Cells were transfected with the indicated oligos, then
the supernatants were removed at 24, 48 or 72 h and analysed on a Luminex
Human Cytokine Magnetic 25-Plex Panel (Part No. LHC0009M) per manu-
facturer’s instructions.
Statistics. All statistical analysis was performed using Excel (Microsoft) or Prism
(GraphPad).
Sample size was estimated using a DSS research tool to detect effect size of
25% with an a-error of 5% and b-error of 10%. Animals were randomized for
tumour experiments into groups such that the average tumour sizes and standard
deviations were comparable. Animals that did not have palpable tumours or
tumours that were not palpable or measurable were excluded from further analysis
at the time of randomization. The tumour measurements were not blinded.
Two-tailed Student’s t-test or Mann–Whitney U-test was used to calculate
statistical signiﬁcance. Data that was not normally distributed as assessed by
Shapiro-wilk test (Excel, Real statistics add-in) was evaluated using U-test.
Variance was similar between treatment groups. Survival curves were analysed
using a log-rank test. A P valueo0.05 was considered to be signiﬁcant.
Data availability. The authors declare that data supporting the ﬁndings of this
study are available within the article and the Supplementary Figures.
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